Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%.
Cancer patients are increasingly messaging their oncology care teams through patient portals, but many health systems have started to bill for this messaging.
Metastatic melanoma patients at the highest risk of death are more likely than lower-risk patients to receive immunotherapy near the end of their life.
Patients with advanced melanoma who receive T-VEC prior to surgery have better long-term outcomes than patients treated with surgery alone, updated data suggest.